115 related articles for article (PubMed ID: 38111983)
1. A recurrence-predictive model based on eight genes and tumor mutational burden/microsatellite instability status in Stage II/III colorectal cancer.
Gao Z; Wan Z; Yu P; Shang Y; Zhu G; Jiang H; Chen Y; Wang S; Lei F; Huang W; Zeng Q; Wang Y; Rong W; Hong Y; Gao Q; Niu P; Zhai Z; An K; Ding C; Wang Y; Gu G; Wang X; Meng Q; Ye S; Liu H; Gu J
Cancer Med; 2024 Jan; 13(1):e6720. PubMed ID: 38111983
[TBL] [Abstract][Full Text] [Related]
2. A novel 9-gene signature for the prediction of postoperative recurrence in stage II/III colorectal cancer.
Xin C; Lai Y; Ji L; Wang Y; Li S; Hao L; Zhang W; Meng R; Xu J; Hong Y; Lou Z
Front Genet; 2022; 13():1097234. PubMed ID: 36704343
[No Abstract] [Full Text] [Related]
3. The Role of Cancer-Elicited Inflammatory Biomarkers in Predicting Early Recurrence Within Stage II-III Colorectal Cancer Patients After Curable Resection.
Ying HQ; Liao YC; Sun F; Peng HX; Cheng XX
J Inflamm Res; 2021; 14():115-129. PubMed ID: 33500648
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a 12-gene expression signature to predict colon cancer prognosis.
Sun D; Chen J; Liu L; Zhao G; Dong P; Wu B; Wang J; Dong L
PeerJ; 2018; 6():e4942. PubMed ID: 29915691
[TBL] [Abstract][Full Text] [Related]
5. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
6. Tumor mutation burden determined by a 645-cancer gene panel and compared with microsatellite instability and mismatch repair genes in colorectal cancer.
Zhou Z; Li K; Wei Q; Chen L; Shuai Y; Wang Y; He K; Si L; Zhong Y; Lu J
J Gastrointest Oncol; 2021 Dec; 12(6):2775-2787. PubMed ID: 35070406
[TBL] [Abstract][Full Text] [Related]
7. A novel 4-gene prognostic signature for hypermutated colorectal cancer.
Ge W; Cai W; Bai R; Hu W; Wu D; Zheng S; Hu H
Cancer Manag Res; 2019; 11():1985-1996. PubMed ID: 30881123
[TBL] [Abstract][Full Text] [Related]
8. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
9. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
[TBL] [Abstract][Full Text] [Related]
10. Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.
Lee DW; Han SW; Bae JM; Jang H; Han H; Kim H; Bang D; Jeong SY; Park KJ; Kang GH; Kim TY
Clin Cancer Res; 2019 Oct; 25(20):6141-6147. PubMed ID: 31285374
[TBL] [Abstract][Full Text] [Related]
11. Prognostic models based on postoperative circulating tumor cells can predict poor tumor recurrence-free survival in patients with stage II-III colorectal cancer.
Wang D; Yang Y; Jin L; Wang J; Zhao X; Wu G; Zhang J; Kou T; Yao H; Zhang Z
J Cancer; 2019; 10(19):4552-4563. PubMed ID: 31528219
[No Abstract] [Full Text] [Related]
12. Evaluation of Long-Term Outcomes of Microsatellite Instability Status in an Asian Cohort of Sporadic Colorectal Cancers.
Tan WJ; Hamzah JL; Acharyya S; Foo FJ; Lim KH; Tan IBH; Tang CL; Chew MH
J Gastrointest Cancer; 2018 Sep; 49(3):311-318. PubMed ID: 28550452
[TBL] [Abstract][Full Text] [Related]
13. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
Alwers E; Jansen L; Bläker H; Kloor M; Tagscherer KE; Roth W; Boakye D; Herpel E; Grüllich C; Chang-Claude J; Brenner H; Hoffmeister M
Mol Oncol; 2020 Feb; 14(2):363-372. PubMed ID: 31816156
[TBL] [Abstract][Full Text] [Related]
15. Identification of Positively and Negatively Selected Driver Gene Mutations Associated With Colorectal Cancer With Microsatellite Instability.
Jonchere V; Marisa L; Greene M; Virouleau A; Buhard O; Bertrand R; Svrcek M; Cervera P; Goloudina A; Guillerm E; Coulet F; Landman S; Ratovomanana T; Job S; Ayadi M; Elarouci N; Armenoult L; Merabtene F; Dumont S; Parc Y; Lefèvre JH; André T; Fléjou JF; Guilloux A; Collura A; de Reyniès A; Duval A
Cell Mol Gastroenterol Hepatol; 2018; 6(3):277-300. PubMed ID: 30116770
[TBL] [Abstract][Full Text] [Related]
16. An Individualized EMT-Related Gene Signature to Predict Recurrence-Free Survival in Stage II/III Colorectal Cancer Patients.
Zhang W; Zhang X; Zhao D; Hu M; Ge X; Xia L
Dig Dis Sci; 2022 Nov; 67(11):5116-5126. PubMed ID: 35094253
[TBL] [Abstract][Full Text] [Related]
17. Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients.
Johansen AFB; Kassentoft CG; Knudsen M; Laursen MB; Madsen AH; Iversen LH; Sunesen KG; Rasmussen MH; Andersen CL
BMC Cancer; 2019 Oct; 19(1):971. PubMed ID: 31638937
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs Expression Patterns Predict Tumor Mutational Burden in Colorectal Cancer.
Huang J; Liu H; Zhao Y; Luo T; Liu J; Liu J; Pan X; Tang W
Front Oncol; 2020; 10():550986. PubMed ID: 33634010
[TBL] [Abstract][Full Text] [Related]
19. A Prediction Model for Tumor Recurrence in Stage II-III Colorectal Cancer Patients: From a Machine Learning Model to Genomic Profiling.
Chen PC; Yeh YM; Lin BW; Chan RH; Su PF; Liu YC; Lee CT; Chen SH; Lin PC
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203549
[TBL] [Abstract][Full Text] [Related]
20. Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis.
Chen YF; Yu ZL; Lv MY; Cai ZR; Zou YF; Lan P; Wu XJ; Gao F
Mol Med; 2021 Oct; 27(1):139. PubMed ID: 34717544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
